AstraZeneca Pharma India gains on import nod for cancer drug
24/09/2024 04:57
** Shares of AstraZeneca Pharma India ASTR.NS up 7% to
7225 rupees
** Drugmaker gets India govt permission to import Durvalumab
120 mg and 500 mg solution for infusion (Imfinzi)
** Import nod for sale, distribution, ASTR says
** Durvalumab is a drug used in treatment of cancers such as
liver and gall bladder cancers
** YTD stock has gained ~31%
(Reporting by Hritam Mukherjee in Bengaluru)
((Hritam.Mukherjee@thomsonreuters.com;))
Recent news on Astrazeneca Pharma India
See all newsBrief: Astrazeneca Pharma Gets Permission To Import For Sale Of Trastuzumab Deruxtecan
India's Astrazeneca Pharma logs worst slide in two months on quarterly profit drop
Brief: Astrazeneca Pharma India March-Quarter PAT 448.8 Million Rupees
Brief: Astrazeneca Pharma India Recommends Dividend Of 36 Rupees Per Equity Share For Fy2025-26
Brief: Astrazeneca Pharma India Receives Permission To Import Durvalumab (Imfinzi) For Additional Indication